Press release
May 8, 2012
CorPath Precise Trial Selected as Late-Breaking Clinical Trial at SCAI 2012

Data demonstrates safety and efficacy of robotic-assisted percutaneous coronary interventions, while enhancing control and radiation protection for interventional cardiologists

NATICK, Mass. — May 8, 2012 — Corindus Vascular Robotics, a leading developer of precision vascular robotics, today announced that the CorPath® PRECISE Trial has been selected as a late breaking clinical trial at The Society for Cardiovascular Angiography and Interventions' (SCAI) Scientific Sessions. Dr. Giora Weisz, director of Clinical Cardiovascular Research at the Center for Interventional Vascular Therapy at NewYork-Presbyteria n Hospital/Columbia University Medical Center and the co-principal investigator of the trial will present data demonstrating that its CorPath®200 System can safely assist interventional cardiologists in performing percutaneous coronary interventions (PCI) procedures. The presentation will take place on Thursday, May 10 at 12:13 p.m. in room MEC B at Mirage Hotel and Convention Center in Las Vegas.

"This study has the potential to transform the way interventional cardiologists will perform PCI procedures," said Dr. Weisz. "Data from the CorPath PRECISE Trial has demonstrated the safety and efficacy of robotic-assisted PCI procedures in a large multi-center study. Additionally, the study demonstrated the CorPath 200 System provides physicians with additional control and significant protection against harmful radiation exposure."

The CorPath 200 System allows interventional cardiologists to perform PCI procedures in a comfortable seated position in a radiation-protected cockpit. In addition to providing an optimal view of the monitors, physicians utilize a joystick to perform precise robotic-assisted placements of coronary guidewires and stent/balloon catheters.

"According to recent data, the high level of radiation and the physical stresses of the cath lab can result in an interventional cardiologist's development of orthopedic problems, cataracts and cancer," said J. Jeffrey Marshall, M.D., FSCAI of the Northeast Georgia Heart Center and investigator of the trial. "The CorPath 200 System addresses a need to provide better radiation protection for physicians, while enhancing the precision and control of stent and guidewire positioning—this has the potential to ultimately enhance patient care."

"We are honored to be selected as one of SCAI's late breaking clinical trials," said David M. Handler, President and CEO of Corindus. "We believe the results of the CorPath PRECISE trial demonstrate the technology's potential to transform the standard of care, and provide interventional cardiologists the ability to improve the health and safety of the cath lab. The feedback from our investigators and the recognition from the society further support our progress."

To learn more about the CorPath 200 System or reserve hands-on demonstrations of the CorPath 200 System at booth 520, please call 508.653.3335 x200 or email

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."

For additional information, visit, and follow @CorindusInc.

Forward Looking Statements

Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event

Examples of such statements include statements:

  • that the level of precision that can be attained using the CorPath GRX technology, combined with the potential for remote capabilities in the future, will both expand and improve how patients are treated;
  • that Corindus has entered a transformational period with a focus on expanding its reach to partner with hospitals to build robotic programs globally;
  • that the successful completion of these procedures at Fu Wai Hospital is the first step in Corindus' growth strategy within China; and that
  • the precise positioning enhancements to the CorPath platform that allows physicians to adjust guide catheters during PCI procedures may expand the use of the CorPath GRX System to more complex cases.

Media Contacts:

Corindus Vascular Robotics, Inc.

Kate Stanton
(508) 653-3335 ext. 200

Investor Contact:

Lynn Pieper Lewis
(415) 937-5402
close the window

Please complete the form below in order to download the content.

close the window

Please complete the form below in order to download the content.

close the window

Please fill out this brief form to subscribe to our email newsletter. By submitting this form, I consent to receive email communications from Corindus.

close the window

Please complete the form below and a member of our Clinical team will contact you.

close the window

Please complete the form below in order to download the content.

close the window

The page you wish to view contains content that is not available in all regions. Please select your region.

close the window